Giovanni Marasco, UEG Week 2022: Findings from the GI-COVID-19 Study

The GI-COVID-19 study (ClinicalTrials.gov NCT04691895) was a prospective, multicenter, controlled study investigating the prevalence of gastrointestinal (GI) symptoms in hospitalized patients with COVID-19. We were delighted to talk with Dr. Giovanni Marasco (Sant’Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy) to discuss the aims, methodology and findings in terms of prevalence of GI symptoms in patients with COVID-19 and post-infection irritable bowel syndrome.

The abstract entitled ‘POST-INFECTION IRRITABLE BOWEL SYNDROME IN SARS-COV-2 PATIENTS: THE GI-COVID19 STUDY’ (Abstract no: OP138) was presented at UEG Week, October 8 – 11, 2022.

Questions

1. What gastrointestinal (GI) symptoms have been associated with COVID-19? (0:27)
2. What were the aims and methodology of the GI-COVID-19 study? (1:14)
3. What were the findings in terms of prevalence of GI symptoms in patients with COVID-19, and post-infection irritable bowel syndrome? (2:29)
4. What were the findings at follow-up and which factors were associated with nausea persistence in COVID-19? (3:28)

Disclosures: Giovanni Marasco has nothing to disclose in relation to this video interview.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.

Filmed as a highlight of UEG Week 2022.